Axsome Therapeutics News

Neurocrine Biosciences Upgraded at Wells Fargo on Pipeline

Seeking AlphaApr 24 11:59 ET

Auvelity's Strong Performance Sustains Buy Rating for Axsome Therapeutics

TipRanksApr 16 02:56 ET

Axsome Therapeutics Analyst Ratings

BenzingaApr 10 09:33 ET

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Axsome Therapeutics (AXSM) and Premier (PINC)

TipRanksApr 10 02:21 ET

Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)

TipRanksApr 8 22:10 ET

Axsome Therapeutics Analyst Ratings

BenzingaApr 2 08:52 ET

Buy Rating Affirmed for Axsome Therapeutics Amid Strong Clinical Pipeline and Market Expansion Potential

TipRanksApr 2 06:26 ET

Axsome Therapeutics Analyst Ratings

BenzingaMar 28 10:05 ET

Mizuho Securities Ups Price Target on Axsome Therapeutics to $109 From $108, Keeps Buy Rating

MT NewswiresMar 28 08:18 ET

Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Axsome Therapeutics (AXSM) and Olink Holding (OLK)

TipRanksMar 27 03:10 ET

Citigroup Adjusts Price Target on Axsome Therapeutics to $127 From $125, Maintains Buy Rating

MT NewswiresMar 26 08:47 ET

RBC Lifts Price Target on Axsome Therapeutics to $128 From $123, Says AXS-12 Reaching Primary Endpoint 'Should Enable Approval,' Keeps Outperform Rating

MT NewswiresMar 26 07:48 ET

Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC)

TipRanksMar 26 06:40 ET

Buy Rating Affirmed for Axsome Therapeutics With Increased Target Price Following Strong AXS-12 Trial Results

TipRanksMar 26 06:16 ET

Axsome Therapeutics Analyst Ratings

BenzingaMar 26 06:13 ET

Maintaining Hold on Axsome Therapeutics: Weighing AXS-12's Modest Efficacy Against Competitive and Market Risks

TipRanksMar 26 04:55 ET

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Sensei Biotherapeutics (SNSE)

TipRanksMar 25 21:20 ET

Axsome Therapeutics Analyst Ratings

BenzingaMar 20 06:44 ET

Baird Initiates Axsome Therapeutics With Outperform Rating, Price Target Is $108

MT NewswiresMar 19 08:51 ET

Axsome Therapeutics Analyst Ratings

BenzingaMar 19 04:46 ET